{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=4",
    "query": {
      "condition": "Ovarian Cancer",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 2464,
    "total_pages": 247,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T15:30:46.710Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03956095",
      "title": "Study of Nutritional Supplement Shakes in People About to Receive Their Debulking Surgery for Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Debulking Surgery for Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Ensure Surgery Immunonutrition Shake supplements",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Daily Food Intake form",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 23,
      "start_date": "2019-05-16",
      "completion_date": "2025-12-19",
      "has_results": false,
      "last_update_posted_date": "2025-12-30",
      "last_synced_at": "2026-10-25T15:30:46.710Z",
      "location_count": 8,
      "location_summary": "Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03956095"
    },
    {
      "nct_id": "NCT00028405",
      "title": "Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Liver Metastasis",
        "Pelvic Cancer",
        "Head and Neck Cancer",
        "Sarcoma",
        "Rectal Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Mouth Cancer"
      ],
      "interventions": [
        {
          "name": "LS 11(Taporfin Sodium)",
          "type": "DRUG"
        },
        {
          "name": "Lumaflex Light Delivery Catheter",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Light Sciences LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2001-11",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-25T15:30:46.710Z",
      "location_count": 6,
      "location_summary": "Tucson, Arizona • Detroit, Michigan • Greenville, North Carolina + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00028405"
    },
    {
      "nct_id": "NCT01509066",
      "title": "Healthy Eating for Reproductive Health (HERHealth)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Polycystic Ovarian Syndrome",
        "Infertility",
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "Diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2012-01",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2019-04-18",
      "last_synced_at": "2026-10-25T15:30:46.710Z",
      "location_count": 1,
      "location_summary": "Columbia, South Carolina",
      "locations": [
        {
          "city": "Columbia",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01509066"
    },
    {
      "nct_id": "NCT05446870",
      "title": "Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High-grade Serous Ovarian Carcinoma",
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Avastin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MK-4830",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 160,
      "start_date": "2022-07-25",
      "completion_date": "2024-10-16",
      "has_results": true,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-10-25T15:30:46.710Z",
      "location_count": 12,
      "location_summary": "Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05446870"
    },
    {
      "nct_id": "NCT02033551",
      "title": "A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Colon Cancer",
        "Lung Cancer",
        "Gastric Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Veliparib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 47,
      "start_date": "2013-12",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2016-09-27",
      "last_synced_at": "2026-10-25T15:30:46.710Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • San Antonio, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02033551"
    },
    {
      "nct_id": "NCT00028496",
      "title": "Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenocarcinoma of the Colon",
        "Adenocarcinoma of the Gallbladder",
        "Adenocarcinoma of the Pancreas",
        "Adenocarcinoma of the Rectum",
        "Adult Primary Hepatocellular Carcinoma",
        "Advanced Adult Primary Liver Cancer",
        "Cholangiocarcinoma of the Gallbladder",
        "Diffuse Adenocarcinoma of the Stomach",
        "Intestinal Adenocarcinoma of the Stomach",
        "Male Breast Cancer",
        "Mixed Adenocarcinoma of the Stomach",
        "Ovarian Endometrioid Adenocarcinoma",
        "Paget Disease of the Breast With Intraductal Carcinoma",
        "Paget Disease of the Breast With Invasive Ductal Carcinoma",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Breast Cancer",
        "Recurrent Colon Cancer",
        "Recurrent Gallbladder Cancer",
        "Recurrent Gastric Cancer",
        "Recurrent Malignant Testicular Germ Cell Tumor",
        "Recurrent Pancreatic Cancer",
        "Recurrent Rectal Cancer",
        "Recurrent Salivary Gland Cancer",
        "Salivary Gland Adenocarcinoma",
        "Stage II Malignant Testicular Germ Cell Tumor",
        "Stage II Pancreatic Cancer",
        "Stage III Colon Cancer",
        "Stage III Gastric Cancer",
        "Stage III Malignant Testicular Germ Cell Tumor",
        "Stage III Pancreatic Cancer",
        "Stage III Rectal Cancer",
        "Stage III Salivary Gland Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IV Breast Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Pancreatic Cancer",
        "Stage IV Rectal Cancer",
        "Stage IV Salivary Gland Cancer",
        "Thyroid Gland Medullary Carcinoma",
        "Unresectable Gallbladder Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant fowlpox-CEA(6D)/TRICOM vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant fowlpox GM-CSF vaccine adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2001-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-25",
      "last_synced_at": "2026-10-25T15:30:46.710Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00028496"
    },
    {
      "nct_id": "NCT07142603",
      "title": "Appetite Response to Meals With Different Protein Sources in Women With PCOS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome (PCOS)"
      ],
      "interventions": [
        {
          "name": "Metabolic response to protein source",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Arkansas, Fayetteville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2025-08-18",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-10-25T15:30:46.710Z",
      "location_count": 1,
      "location_summary": "Fayetteville, Arkansas",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07142603"
    },
    {
      "nct_id": "NCT03861403",
      "title": "A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Advanced Triple Negative Breast Cancer",
        "Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer",
        "Advanced Metastatic Castration-Resistant Prostate Cancer",
        "Advanced Platinum-Resistant Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "TRX518",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Leap Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2019-05-20",
      "completion_date": "2020-07-14",
      "has_results": false,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-10-25T15:30:46.710Z",
      "location_count": 4,
      "location_summary": "Lafayette, Indiana • New York, New York • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03861403"
    },
    {
      "nct_id": "NCT02607813",
      "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NSCLC",
        "Ovarian Cancer",
        "Melanoma",
        "Other Solid Tumors"
      ],
      "interventions": [
        {
          "name": "LXH254",
          "type": "DRUG"
        },
        {
          "name": "PDR001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 142,
      "start_date": "2016-01-18",
      "completion_date": "2022-02-19",
      "has_results": false,
      "last_update_posted_date": "2022-12-21",
      "last_synced_at": "2026-10-25T15:30:46.710Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02607813"
    },
    {
      "nct_id": "NCT04997096",
      "title": "Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Ovarian Carcinoma",
        "Ovarian Cancer Stage IV",
        "Ovarian Cancer Stage III",
        "Ovarian Cancer Stage 3",
        "Endometrial Cancer",
        "Endometrial Cancer Stage"
      ],
      "interventions": [
        {
          "name": "Exercise",
          "type": "OTHER"
        },
        {
          "name": "Attention Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2022-04-02",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-10-25T15:30:46.710Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04997096"
    }
  ]
}